CIL is a member of dicarboxylate-containing angiotensin-converting enzyme inhibitors (ACE-Is) - an appreciated group of pharmaceuticals used as first-line therapy in a wide array of cardiovascular-system related diseases, including: hypertension, symptomatic heart failure, diabetic and non-diabetic nephropathy as well as in the secondary prevention after acute myocardial infarction (22, 23). The gene discussed is ACE; the disease is acute myocardial infarction.